Bristol-Myers Squibb has been touted as a potential takeover target in the pharma industry – and potential buyers may take note of the continued strong performance of its cancer drug Opdivo
AstraZeneca had placed its immunotherapy Imfinzi (durvalumab) at the centre of its efforts to rebuild its sales – but after a shock failure last year in first line lung cancer, the drug has
